Background

• Adjuvant endocrine therapy (AET) is widely used among approximately 80% of breast cancer patients with hormone receptor-positive tumours.
• AET cuts the risk for recurrence by 30% and mortality by 40%.
• The main types of AET are tamoxifen and aromatase inhibitors (AIs), with or without gonadotropin-releasing hormone (GnRH) agonists.

Takeaway

• Side...